DK1601355T3 - Diagnostisk metode til forudsigelse af nyretransplantationsafstödning - Google Patents

Diagnostisk metode til forudsigelse af nyretransplantationsafstödning

Info

Publication number
DK1601355T3
DK1601355T3 DK04716242T DK04716242T DK1601355T3 DK 1601355 T3 DK1601355 T3 DK 1601355T3 DK 04716242 T DK04716242 T DK 04716242T DK 04716242 T DK04716242 T DK 04716242T DK 1601355 T3 DK1601355 T3 DK 1601355T3
Authority
DK
Denmark
Prior art keywords
diagnostic method
transplant rejection
renal transplant
predicting renal
predicting
Prior art date
Application number
DK04716242T
Other languages
Danish (da)
English (en)
Inventor
Andrea Galli
Paola Romagnani
Mario Serio
Calogero Surrenti
Original Assignee
Univ Firenze
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Firenze filed Critical Univ Firenze
Application granted granted Critical
Publication of DK1601355T3 publication Critical patent/DK1601355T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
DK04716242T 2003-03-06 2004-03-02 Diagnostisk metode til forudsigelse af nyretransplantationsafstödning DK1601355T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000058A ITFI20030058A1 (it) 2003-03-06 2003-03-06 Formulazioni farmaceutiche contenenti tiazolidinedioni
PCT/EP2004/002069 WO2004078175A2 (en) 2003-03-06 2004-03-02 Pharmaceutical preparations containing thiazolidinediones for the treatment or prevention of ip-10 mediated diseases

Publications (1)

Publication Number Publication Date
DK1601355T3 true DK1601355T3 (da) 2007-12-17

Family

ID=32948189

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04716242T DK1601355T3 (da) 2003-03-06 2004-03-02 Diagnostisk metode til forudsigelse af nyretransplantationsafstödning

Country Status (14)

Country Link
US (1) US20060287372A1 (de)
EP (2) EP1601355B1 (de)
JP (1) JP2006519799A (de)
AT (1) ATE368859T1 (de)
AU (1) AU2004216823B2 (de)
CA (1) CA2518199A1 (de)
CY (1) CY1108098T1 (de)
DE (1) DE602004007895T2 (de)
DK (1) DK1601355T3 (de)
ES (1) ES2290678T3 (de)
IT (1) ITFI20030058A1 (de)
PL (1) PL1601355T3 (de)
PT (1) PT1601355E (de)
WO (1) WO2004078175A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
ITFI20040243A1 (it) * 2004-11-25 2005-02-25 Paola Romagnani Metodo diagnostico per la previsione di rigetto di organo trapiantato
GB0504206D0 (en) * 2005-03-01 2005-04-06 Glaxo Group Ltd Combination therapy
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
NZ571870A (en) 2006-03-16 2011-07-29 Metabolic Solutions Dev Co Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
JP5366269B2 (ja) 2007-09-14 2013-12-11 ジャンセン ファーマシューティカルズ， インコーポレイテッド． １，３−二置換４−（アリル−ｘ−フェニル）−１ｈ−ピリジン−２−オン
CN101801930B (zh) 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-二取代的-4-苯基-1h-吡啶-2-酮
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2010025890A1 (en) 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MX2011011962A (es) 2009-05-12 2012-02-28 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2).
SG10201402250TA (en) 2009-05-12 2014-07-30 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2643320B1 (de) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridinderivate und ihre verwendung als positiv allosterische modulatoren des mglur2 receptors
ES2552879T3 (es) 2010-11-08 2015-12-02 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EA201891617A3 (ru) 2014-01-21 2019-04-30 Янссен Фармацевтика Нв Комбинации, содержащие положительные аллостерические модуляторы или ортостерические агонисты метаботропного глутаматергического рецептора 2 подтипа, и их применение
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
WO2018130679A1 (en) * 2017-01-16 2018-07-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing cd95- mediated cell motility

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2682695A (en) * 1994-06-20 1996-01-15 Takeda Chemical Industries Ltd. Condensed imidazole compounds, their production and use
CN1226833A (zh) * 1996-05-31 1999-08-25 三共株式会社 自身免疫疾病治疗剂
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
WO2000030628A2 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
AU7995300A (en) * 1999-10-05 2001-05-10 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
EP1234060A2 (de) * 1999-11-30 2002-08-28 OXO Chemie AG Auswertung und voraussagung von klinischen ergebnissen durch gen expresion analyse
US20020006942A1 (en) * 2000-02-24 2002-01-17 Davis Roger A. Methods of treating liver disorders and disorders associated with liver function
US20020019344A1 (en) * 2000-02-26 2002-02-14 Pershadsingh Harrihar A. Methods of preventing allograft rejection
US20020018776A1 (en) * 2000-04-14 2002-02-14 Millennium Pharmaceuticals, Inc. Method of treating graft rejection using inhibitors of CXCR3 function
FR2823225B1 (fr) * 2001-04-04 2004-09-17 Pierre Desreumaux Utilisation de composes modulant l'activite de l'heterodimere rxr-ppar a titre de medicament pour le traitement de l'hepatite c, et procede de criblage correspondant
US7244555B2 (en) * 2002-05-14 2007-07-17 Renovak Inc Systems and methods for identifying organ transplant risk

Also Published As

Publication number Publication date
PL1601355T3 (pl) 2007-12-31
DE602004007895T2 (de) 2008-04-17
PT1601355E (pt) 2007-11-15
AU2004216823B2 (en) 2009-07-16
WO2004078175A2 (en) 2004-09-16
DE602004007895D1 (de) 2007-09-13
EP1601355B1 (de) 2007-08-01
WO2004078175A3 (en) 2004-12-09
US20060287372A1 (en) 2006-12-21
ITFI20030058A1 (it) 2004-09-07
CY1108098T1 (el) 2014-02-12
ATE368859T1 (de) 2007-08-15
CA2518199A1 (en) 2004-09-16
JP2006519799A (ja) 2006-08-31
EP1601355A2 (de) 2005-12-07
AU2004216823A1 (en) 2004-09-16
ES2290678T3 (es) 2008-02-16
EP1830191A2 (de) 2007-09-05
EP1830191A3 (de) 2007-10-03

Similar Documents

Publication Publication Date Title
CY1108098T1 (el) Διαγνωστικη μεθοδος για την προβλεψη της απορριψης μεταμοσχευσεων νεφρου
CY1116107T1 (el) Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων
DE602004020332D1 (de) Neue heterozyklische verbindungen, die sich für die behandlung von entzündlichen und allergischen erkrankungen eignen: verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
DK1656372T3 (da) 2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme
FR2850009B1 (fr) Ensemble de traitement de la degenerescence d'un disque intervertebral
DK1131096T3 (da) Anti-CD20-antistofbehandling af patienter, der modtager knoglemarvs- eller periferisk blodstamcelletransplantationer
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
ATE457989T1 (de) Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit
ATE417037T1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
ATE537826T1 (de) Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
DE60225561D1 (de) Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel, zwischenprodukten und verfahren zur herstellung
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
DK1592384T3 (da) Cop 1 til behandling af inflammatoriske tarmsygdomme
EA200501690A1 (ru) Композиция, включающая ингибитор pde4 и ингибитор pde5
ATE313540T1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
NL1026203A1 (nl) Verbindingen toepasbaar voor de behandeling van ziekten.
DE60326069D1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
DE60218375D1 (de) Pharmazeutische Zusammensetzung zur Behandlung gynäkologischer Erkrankungen
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine
DE60309719D1 (de) N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis